CN1606569A - 具有mn结合和细胞粘附中和活性的人类抗体 - Google Patents

具有mn结合和细胞粘附中和活性的人类抗体 Download PDF

Info

Publication number
CN1606569A
CN1606569A CNA028254880A CN02825488A CN1606569A CN 1606569 A CN1606569 A CN 1606569A CN A028254880 A CNA028254880 A CN A028254880A CN 02825488 A CN02825488 A CN 02825488A CN 1606569 A CN1606569 A CN 1606569A
Authority
CN
China
Prior art keywords
seq
nos
antibody
host cell
human antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028254880A
Other languages
English (en)
Chinese (zh)
Inventor
T·塔克伊基
N·杜布瓦－斯特林费罗
J·E·默菲
J·林肯伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of CN1606569A publication Critical patent/CN1606569A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA028254880A 2001-10-18 2002-10-18 具有mn结合和细胞粘附中和活性的人类抗体 Pending CN1606569A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34365701P 2001-10-18 2001-10-18
US60/343,657 2001-10-18
US37771602P 2002-05-02 2002-05-02
US60/377,716 2002-05-02

Publications (1)

Publication Number Publication Date
CN1606569A true CN1606569A (zh) 2005-04-13

Family

ID=26993561

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028254880A Pending CN1606569A (zh) 2001-10-18 2002-10-18 具有mn结合和细胞粘附中和活性的人类抗体

Country Status (18)

Country Link
US (2) US7462696B2 (https=)
EP (1) EP1438339A4 (https=)
JP (2) JP2005528884A (https=)
KR (1) KR20050037478A (https=)
CN (1) CN1606569A (https=)
AR (1) AR036833A1 (https=)
BR (1) BR0213968A (https=)
CA (1) CA2463943A1 (https=)
CO (1) CO5370684A1 (https=)
DO (1) DOP2002000494A (https=)
HU (1) HUP0600335A2 (https=)
IL (1) IL161411A0 (https=)
MX (1) MXPA04003508A (https=)
PE (1) PE20030473A1 (https=)
PL (1) PL374304A1 (https=)
RU (1) RU2317998C2 (https=)
UY (1) UY27499A1 (https=)
WO (1) WO2003033674A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102585001B (zh) * 2005-12-12 2014-08-27 拜尔健康护理有限责任公司 抗mn抗体和使用它们的方法
CN114137205A (zh) * 2014-04-03 2022-03-04 艾勒詹尼斯有限责任公司 用于检测食物变态反应的肽、试剂和方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7504364B2 (en) 2002-03-01 2009-03-17 Receptors Llc Methods of making arrays and artificial receptors
US7469076B2 (en) 2003-09-03 2008-12-23 Receptors Llc Sensors employing combinatorial artificial receptors
WO2004075855A2 (en) * 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
EP1613737A4 (en) 2003-03-28 2008-12-03 Receptors Llc ARTIFICIAL RECEPTORS COMPRISING REVERSIBLE IMMOBILIZED CONSTRUCTION BLOCKS AND METHODS
EP1664778A2 (en) * 2003-09-03 2006-06-07 Receptors LLC Nanodevices employing combinatorial artificial receptors
US7884052B2 (en) 2004-09-03 2011-02-08 Receptors Llc Combinatorial artificial receptors including tether building blocks on scaffolds
EP1789792A2 (en) 2004-09-11 2007-05-30 Receptors LLC Combinatorial artificial receptors including peptide building blocks
US20140273033A1 (en) * 2007-04-12 2014-09-18 Universiteit Hasselt Biomarkers for multiple sclerosis
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
EP2285409B1 (en) * 2008-05-30 2016-04-20 XBiotech, Inc Il-1 alpha antibodies
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69120146T2 (de) * 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6297051B1 (en) * 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
AU2861695A (en) * 1994-06-15 1996-01-05 Ciba Corning Diagnostics Corp. Mn gene and protein
ES2296412T3 (es) * 1998-10-23 2008-04-16 Institute Of Virology Gen y proteina mn.
US6689744B2 (en) * 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102585001B (zh) * 2005-12-12 2014-08-27 拜尔健康护理有限责任公司 抗mn抗体和使用它们的方法
CN114137205A (zh) * 2014-04-03 2022-03-04 艾勒詹尼斯有限责任公司 用于检测食物变态反应的肽、试剂和方法

Also Published As

Publication number Publication date
US20030077277A1 (en) 2003-04-24
HUP0600335A2 (en) 2006-08-28
PE20030473A1 (es) 2003-06-26
DOP2002000494A (es) 2004-05-31
JP2010260845A (ja) 2010-11-18
CA2463943A1 (en) 2003-04-24
PL374304A1 (en) 2005-10-03
US20100240100A1 (en) 2010-09-23
UY27499A1 (es) 2003-05-30
WO2003033674A3 (en) 2003-08-21
KR20050037478A (ko) 2005-04-22
MXPA04003508A (es) 2004-07-22
IL161411A0 (en) 2004-09-27
RU2317998C2 (ru) 2008-02-27
CO5370684A1 (es) 2004-02-27
EP1438339A2 (en) 2004-07-21
RU2004115112A (ru) 2005-04-27
WO2003033674A2 (en) 2003-04-24
EP1438339A4 (en) 2008-08-27
AR036833A1 (es) 2004-10-06
BR0213968A (pt) 2005-05-10
JP2005528884A (ja) 2005-09-29
US7462696B2 (en) 2008-12-09

Similar Documents

Publication Publication Date Title
CN1606569A (zh) 具有mn结合和细胞粘附中和活性的人类抗体
CN1229391C (zh) 涉及α6β4整联蛋白的人胃肠上皮肿瘤抗原的抗体
CN1187374C (zh) 人源化的特异于人4－1bb的抗体和含有它的药物组合物
CN1809592A (zh) 识别n－乙醇酰gm3神经节苷脂的重组抗体和片段以及其在肿瘤诊断和治疗上的应用
CN1308448C (zh) 低分子化的tpo激动剂抗体
CN1241944C (zh) 抗人白介素－5受体α链的抗体
CN1271205C (zh) 重新构建的人抗hm1.24抗体
CN1678634A (zh) 免疫球蛋白单个变体抗原结合区及其特异性构建体
CN101074261A (zh) Trail受体1和/或trail受体2特异性抗体及其应用
CN1823163A (zh) 针对胰岛素样生长因子ⅰ受体的抗体及其应用
CN1252076A (zh) 抗人抗原受体的新的生产方法及其用途
CN1596313A (zh) 人源化的胶原抗体及相关方法
CN1547590A (zh) 人源化抗-LT-β-R抗体
CN1688338A (zh) 对免疫系统分子进行人源化的方法
CN1829806A (zh) 产生高亲和力抗体的方法
CN1671837A (zh) 抗胰岛素样生长因子受体(igfr)的人源中和抗体
CN1662556A (zh) 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN1656122A (zh) 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
CN101035809A (zh) 抗tag－72的人源化单克隆抗体
CN1607959A (zh) 导致或引起包括淋巴瘤细胞在内的细胞杀伤的人多肽
CN1886426A (zh) 结合白细胞介素－4受体的抗体
CN1076966A (zh) 抗人白细胞介素-4的人性化单克隆抗体的克隆和表达
CN1422333A (zh) 诱导细胞凋亡的多肽
CN1283662C (zh) 拮抗性抗hFAS配基人类抗体及其片段
CN1551783A (zh) 治疗多发性骨髓瘤的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication